Imaging Studies of Cognitive Impairment in Parkinson s Disease

Objectives:

The purpose of this protocol is to identify the neural correlates of cognitive impairment in

Parkinson disease (PD) using magnetic resonance imaging (MRI).

Study Population:

We will study 36 PD patients, defined by the UK Parkinson s Society Brain Bank diagnostic

criteria [1], consisting of 12 patients with cognitively normal PD (PD-CogNL), 12 with PD

with mild cognitive impairment (PD-MCI) [2], and 12 with PD with dementia (PDD) [3]. We

will also study 12 age- and gender-matched healthy volunteers (HVs) as controls.

Design:

This is an observational study and includes 3 PD patient subgroups (PD-CogNL, PD-MCI and PDD) and HVs group. Eligible participants will have one visit lasting 2- 4 days, ideally over 2 consecutive days. If the visit cannot be completed within that time frame, a second visit may be scheduled within 3 months to complete the assessments. They will have a clinical assessment, cognitive assessment, and MRI scans.

Outcome Measures and Hypothesis:

The primary outcome measure is the Mini-Mental State Examination (MMSE) score and

functional connectivity of cognitive networks, including default mode network, using restingstate

functional MRI (fMRI). We hypothesize that there is a group difference in functional

connectivity of cognitive networks between the PD patient subgroups and HVs. We also

hypothesize that there is a correlation between the MMSE score and functional connectivity

of the default mode network in PD patients.

Secondary outcome measures are fractional anisotropy (FA) values, functional

connectivity of the cognitive networks during working memory tasks, olfactory function

score and the functional connectivity of olfactory network, and scales of brain perfusion and

the functional connectivity of default mode network. We hypothesize that there: 1) is a group

difference in FA values between PD patient subgroups and the HVs; 2) are group differences

in functional connectivity of the cognitive networks during the working memory task

between PD patient subgroups and HVs; 3) is a correlation between olfactory function and

functional connectivity of the olfactory network in patients with PD-CogNL or PD-MCI; and

• are correlations between brain perfusion and the functional connectivity of the default

mode network in PD patients.

• INCLUSION CRITERIA:

For all subjects:

• Age 40 or older.
• Able to abstain from caffeine and alcohol for 24 hours before each visit.
• English is the first language.
• Right handed

For PD cohort:

• Established diagnosis of PD.
• History compatible with diagnosis of PD
• Present with at least 3 of the following features: bradykinesia, resting tremor, cogwheel rigidity or postural reflex impairment
• One of the 3 clinical features is either bradykinesia or resting tremor
• Currently taking or history of taking dopaminergic therapy with symptomatic response.
• Is able to give informed consent or, if there is evidence of cognitive decline, able to give assent and able to appoint a durable power of attorney (DPA) who can give informed consent.

Exclusion criteria

for all subjects:

• Use of illegal drugs within the past 6 months.
• More than 7 alcoholic drinks a week for females or 14 alcoholic drinks a week for males.
• History of a neurologic disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, a movement disorder, epilepsy or a history of seizures, except PD for PD patients.
• History of any head injury with loss of consciousness.
• Pregnancy or positive pregnancy test before the research procedure due to the risks associated with MRI scans.
• Inability to lie flat on the back for up to 2 hours.
• Claustrophobia or a feeling of discomfort from being in small, enclosed spaces of enough severity to prevent MRI scanning.
• Surgically or traumatically implanted metallic foreign bodies, such as pacemakers, implanted medical pumps, implanted hearing aids, metal plates in the skull or metal implants in the skull or eyes (other than dental fillings) that may be physically hazardous during an MRI, or might distort the images.
• Ablative surgery or implanted electrodes and generator for deep brain stimulation
• Use of the following medications or substances within 6 months of getting MRI scan: e.g., Cocaine, amphetamines, methylphenidate, ephedrine, phentermine, buproprion, fentanyl, ketamine, and phencyclidine. Prescribed medication for common conditions, such as allergy or cold, will not be exclusionary. Prescribed medication for PD will not be exclusionary for PD patient.
• Have uncontrolled head movements that may impair image data collection (for PD patients).
• Subjects with MMSE<26 for HVs.
• Have clinically relevant focal neurological findings on exam that suggest cerebral pathology other than that associated with PD for PD patients.
• Any abnormal or focal finding on neurological exam for HVs.
• Abnormal findings in clinical MRI.
• PD patients with Beck Depression Inventory (BDI)-II > 31 will be excluded, because severe or extreme depression may confound with cognitive function.